Sort by
Items per page

Send to

Choose Destination

Links from PubChem Compound

Items: 1 to 20 of 2504


Long-term Efficacy of Methotrexate Plus Vinblastine/Vinorelbine in a Large Series of Patients Affected by Desmoid-Type Fibromatosis.

Palassini E, Frezza AM, Mariani L, Lalli L, Colombo C, Fiore M, Messina A, Casale A, Morosi C, Collini P, Stacchiotti S, Casali PG, Gronchi A.

Cancer J. 2017 Mar/Apr;23(2):86-91. doi: 10.1097/PPO.0000000000000254.


Health-related quality of life in patients with locally recurrent or metastatic breast cancer treated with etirinotecan pegol versus treatment of physician's choice: Results from the randomised phase III BEACON trial.

Twelves C, Cortés J, O'Shaughnessy J, Awada A, Perez EA, Im SA, Gómez-Pardo P, Schwartzberg LS, Diéras V, Yardley DA, Potter DA, Mailliez A, Moreno-Aspitia A, Ahn JS, Zhao C, Hoch U, Tagliaferri M, Hannah AL, Rugo HS.

Eur J Cancer. 2017 May;76:205-215. doi: 10.1016/j.ejca.2017.02.011. Epub 2017 Mar 27.


Baicalein attenuates vinorelbine-induced vascular endothelial cell injury and chemotherapeutic phlebitis in rabbits.

Ge GF, Shi WW, Yu CH, Jin XY, Zhang HH, Zhang WY, Wang LC, Yu B.

Toxicol Appl Pharmacol. 2017 Mar 1;318:23-32. doi: 10.1016/j.taap.2017.01.013. Epub 2017 Jan 23.


Phase I/II Trial of Sorafenib in Combination with Vinorelbine as First-Line Chemotherapy for Metastatic Breast Cancer.

Ferrario C, Strepponi I, Esfahani K, Charamis H, Langleben A, Scarpi E, Nanni O, Miller WH Jr, Panasci LC.

PLoS One. 2016 Dec 19;11(12):e0167906. doi: 10.1371/journal.pone.0167906. eCollection 2016.


Clonal Evolutionary Analysis during HER2 Blockade in HER2-Positive Inflammatory Breast Cancer: A Phase II Open-Label Clinical Trial of Afatinib +/- Vinorelbine.

Goh G, Schmid R, Guiver K, Arpornwirat W, Chitapanarux I, Ganju V, Im SA, Kim SB, Dechaphunkul A, Maneechavakajorn J, Spector N, Yau T, Afrit M, Ahmed SB, Johnston SR, Gibson N, Uttenreuther-Fischer M, Herrero J, Swanton C.

PLoS Med. 2016 Dec 6;13(12):e1002136. doi: 10.1371/journal.pmed.1002136. eCollection 2016 Dec.


Final Results of the Randomized Phase II NorCap-CA223 Trial Comparing First-Line All-Oral Versus Taxane-Based Chemotherapy for HER2-Negative Metastatic Breast Cancer.

Cinieri S, Chan A, Altundag K, Vandebroek A, Tubiana-Mathieu N, Barnadas A, Dodyk P, Lazzarelli S, Botha M, Rauch D, Villanova G, Coskun U.

Clin Breast Cancer. 2017 Apr;17(2):91-99.e1. doi: 10.1016/j.clbc.2016.06.014. Epub 2016 Jun 25.


Original Vinca Derivatives: From P-Glycoprotein Substrates to P-Glycoprotein Inhibitors.

Gherbovet O, García Alvarez MC, Bignon J, Roussi F.

J Med Chem. 2016 Dec 8;59(23):10774-10780. Epub 2016 Nov 23.


Comparison of the Therapeutic Efficacy of the Early and the Delayed Use of Vinorelbine-Based Regimens for Patients with Advanced Breast Cancer.

Wang Y, Liu J, Jia W, Li S, Rao N, Su F, Liu Q, Yao H.

Chemotherapy. 2017;62(1):71-79. Epub 2016 Sep 21.


Efficacy and safety of vinorelbine-capecitabine oral metronomic combination in elderly metastatic breast cancer patients: VICTOR-1 study.

Cazzaniga ME, Torri V, Riva F, Porcu L, Cicchiello F, Capici S, Cortinovis D, Digiacomo N, Bidoli P.

Tumori. 2017 Jan 21;103(1):e4-e8. doi: 10.5301/tj.5000543.


[Extravasation of a chemotherapeutic drug].

Brahmi SA, Ziani FZ.

Pan Afr Med J. 2016 May 13;24:55. doi: 10.11604/pamj.2016.24.55.8930. eCollection 2016. French. No abstract available.


Targeting bortezomib-induced aggresome formation using vinorelbine enhances the cytotoxic effect along with ER stress loading in breast cancer cell lines.

Miyahara K, Kazama H, Kokuba H, Komatsu S, Hirota A, Takemura J, Hirasawa K, Moriya S, Abe A, Hiramoto M, Ishikawa T, Miyazawa K.

Int J Oncol. 2016 Nov;49(5):1848-1858. doi: 10.3892/ijo.2016.3673. Epub 2016 Aug 29.


Role of 3' repressor sequences of p53 in anti-cancer drug sensitivity of human lung tumor cells.

Wang H, Li W, Lai B, Yang X, Zhang C, Tao H, Zhu Y, Li J.

Gene. 2016 Dec 15;594(2):190-196. doi: 10.1016/j.gene.2016.08.053. Epub 2016 Sep 1.


Concurrent chemoradiotherapy with cisplatin and S-1 or vinorelbine for patients with stage III unresectable non-small cell lung cancer: A retrospective study.

Takase N, Hattori Y, Kiriu T, Itoh S, Kawa Y, Yamamoto M, Urata Y, Shimada T, Tsujino K, Soejima T, Negoro S, Satouchi M.

Respir Investig. 2016 Sep;54(5):334-40. doi: 10.1016/j.resinv.2016.02.008. Epub 2016 Mar 25.


Evaluation of assays for drug efficacy in a three-dimensional model of the lung.

Huber JM, Amann A, Koeck S, Lorenz E, Kelm JM, Obexer P, Zwierzina H, Gamerith G.

J Cancer Res Clin Oncol. 2016 Sep;142(9):1955-66. doi: 10.1007/s00432-016-2198-0. Epub 2016 Jul 16.


Biweekly Pegylated Liposomal Doxorubicin (Caelyx) in Heavily Pretreated Metastatic Breast Cancer: A Phase 2 Study.

Jehn CF, Hemmati P, Lehenbauer-Dehm S, Kümmel S, Flath B, Schmid P.

Clin Breast Cancer. 2016 Dec;16(6):514-519. doi: 10.1016/j.clbc.2016.06.001. Epub 2016 Jun 14.


Bendamustine in Combination With Gemcitabine and Vinorelbine Is an Effective Regimen As Induction Chemotherapy Before Autologous Stem-Cell Transplantation for Relapsed or Refractory Hodgkin Lymphoma: Final Results of a Multicenter Phase II Study.

Santoro A, Mazza R, Pulsoni A, Re A, Bonfichi M, Zilioli VR, Salvi F, Merli F, Anastasia A, Luminari S, Annechini G, Gotti M, Peli A, Liberati AM, Di Renzo N, Castagna L, Giordano L, Carlo-Stella C.

J Clin Oncol. 2016 Sep 20;34(27):3293-9. doi: 10.1200/JCO.2016.66.4466. Epub 2016 Jul 5.


The polysialic acid mimetics 5-nonyloxytryptamine and vinorelbine facilitate nervous system repair.

Saini V, Lutz D, Kataria H, Kaur G, Schachner M, Loers G.

Sci Rep. 2016 Jun 21;6:26927. doi: 10.1038/srep26927.

Supplemental Content

Support Center